Paragon 28 Funding: How Much Did They Raise & Key Investors

How Much Did Paragon 28 Raise?
Funding & Key Investors

Paragon 28 has solidified its position within the specialized orthopedic medical device sector, securing a total capital infusion of $127M. This financial trajectory, punctuated by a recent strategic investment of $125M, underscores the company's robust growth and its commitment to advancing surgical outcomes in the foot and ankle market. By leveraging these resources, the firm continues to scale its operational footprint and expand its portfolio of proprietary surgical systems, catering to the evolving needs of hospitals and ambulatory surgery centers globally.

The recent influx of capital serves as a critical catalyst for the company's ongoing development of high-precision instrumentation and advanced orthobiologics. As Paragon 28 navigates the complexities of the medical device landscape, this financing ensures the necessary liquidity to maintain its competitive edge in a highly specialized niche, reinforcing its reputation as a leader in reconstructive surgical technology.

What is Paragon 28?

Paragon 28

Manufacturing

Medical Devices & Equipment

Founded in 2010 and headquartered in Englewood, Colorado, Paragon 28 is a dedicated developer and distributor of comprehensive foot and ankle surgical systems. The company's extensive product catalog includes sophisticated plating systems, such as the Gorilla and Silverback lines, alongside precision guide technology for complex procedures like bunion correction and Charcot foot reconstruction. Beyond hardware, the firm provides a diverse array of orthobiologics and soft tissue fixation solutions, positioning itself as a holistic partner for orthopedic surgeons. By focusing exclusively on the foot and ankle, Paragon 28 achieves deep clinical penetration, offering specialized tools that address specific anatomical challenges with high-precision engineering.

How much funding has Paragon 28 raised?

Paragon 28 has raised a total of $127M across 2 funding rounds:

2020

Debt

$2M

2021

Stock Offering

$125M

Debt (2020): $2M with participation from PPP

Stock Issuance/Offering (2021): $125M, investors not publicly disclosed

Key Investors in Paragon 28

Undisclosed Investor

An institutional participant providing capital to support the scaling of specialized medical device manufacturing and distribution.

PPP

Public-Private Partnership

Undisclosed Investor

A strategic partner contributing to the firm's capital structure to facilitate ongoing research and development in orthopedic surgical systems.

What's next for Paragon 28?

Looking ahead, Paragon 28 is well-positioned to leverage its recent capital injection to accelerate the commercialization of its next-generation 3D total ankle replacement systems and expanded orthobiologic offerings. The strategic focus remains on deepening market penetration within the United States while exploring international growth opportunities. By prioritizing innovation in bone reconstruction and ligament fixation, the company aims to set new standards for patient recovery and surgical efficiency. As the healthcare sector increasingly shifts toward specialized, minimally invasive procedures, Paragon 28's commitment to technological refinement and clinical excellence will likely remain the primary driver of its long-term value creation and market leadership.

See full Paragon 28 company page

See More Financial Insights